Mazindol

Mazindol
Clinical data
Trade names	Mazanor, Sanorex
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of; administration	By mouth
ATC code	A08AA05 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); BR: Class B2 (Anorectic drugs); CA: Schedule IV; DE: Anlage II (Authorized trade only, not prescriptible); US: Schedule IV; Schedule IV (International);
Pharmacokinetic data
Bioavailability	93%
Metabolism	Hepatic
Elimination half-life	10–13 hours
Excretion	Renal
Identifiers
	IUPAC name (±)-5-(4-chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-ol;
CAS Number	22232-71-9 ;
PubChem CID	4020;
IUPHAR/BPS	4797;
DrugBank	DB00579 ;
ChemSpider	3880 ;
UNII	C56709M5NH;
KEGG	D00367 ;
ChEMBL	ChEMBL781 ;
CompTox Dashboard (EPA)	DTXSID1023237 ;
ECHA InfoCard	100.040.764
Chemical and physical data
Formula	C16H13ClN2O
Molar mass	284.74 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES ClC1=CC=C(C2(C3=CC=CC=C3C4=NCCN42)O)C=C1;
	InChI InChI=1S/C16H13ClN2O/c17-12-7-5-11(6-8-12)16(20)14-4-2-1-3-13(14)15-18-9-10-19(15)16/h1-8,20H,9-10H2 ; Key:ZPXSCAKFGYXMGA-UHFFFAOYSA-N ;
	(verify)

Mazindol, sold under the brand names Mazanor and Sanorex, is a central nervous system (CNS) stimulant which is used as an appetite suppressant. It was developed by Sandoz-Wander in the 1960s. The US Food and Drug Administration approved mazindol in June 1973, but Novartis, the manufacturer, discontinued it in 1999 for reasons unrelated to its efficacy or safety.